万泰生物
(603392)
| 流通市值：321.41亿 | | | 总市值：321.41亿 |
| 流通股本：12.64亿 | | | 总股本：12.64亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,048,467,239.17 | 523,344,880.88 | 1,818,967,457.87 | 1,498,369,947.13 |
| 营业总成本 | 1,176,336,681.53 | 518,061,923.75 | 2,322,416,853.65 | 1,780,002,318.88 |
| 其他经营收益 | | | | |
| 营业利润 | -137,542,397.68 | -58,681,752.57 | -469,223,782.37 | -184,441,733.74 |
| 利润总额 | -137,462,969.55 | -59,869,690.47 | -480,885,756.41 | -191,856,422.75 |
| 净利润 | -132,375,087.05 | -44,887,263.69 | -413,963,529.44 | -173,891,354.56 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | -132,375,087.05 | -44,887,263.69 | -413,963,529.44 | -173,891,354.56 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 6,743,607,102.13 | 6,730,935,816.05 | 7,526,044,987.11 | 7,991,912,888.33 |
| 非流动资产: | | | | |
| 非流动资产合计 | 6,962,823,752.56 | 7,030,061,031.7 | 6,518,011,864.18 | 6,378,844,898.65 |
| 资产总计 | 13,706,430,854.69 | 13,760,996,847.75 | 14,044,056,851.29 | 14,370,757,786.98 |
| 流动负债: | | | | |
| 流动负债合计 | 1,593,928,275.13 | 1,598,064,895.99 | 1,802,229,693.25 | 1,873,989,314.3 |
| 非流动负债: | | | | |
| 非流动负债合计 | 211,804,773.96 | 174,746,322.81 | 208,754,265.39 | 223,623,405.15 |
| 负债合计 | 1,805,733,049.09 | 1,772,811,218.79 | 2,010,983,958.64 | 2,097,612,719.45 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 11,736,292,175.72 | 11,821,624,431.15 | 11,864,608,261.88 | 12,089,453,978.52 |
| 股东权益合计 | 11,900,697,805.6 | 11,988,185,628.96 | 12,033,072,892.65 | 12,273,145,067.53 |
| 负债和股东权益合计 | 13,706,430,854.69 | 13,760,996,847.75 | 14,044,056,851.29 | 14,370,757,786.98 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,186,634,145.06 | 477,044,634.29 | 2,578,952,453.09 | 1,921,052,958.15 |
| 经营活动现金流出小计 | 1,267,958,778.74 | 709,088,870.92 | 2,489,198,409.99 | 1,913,768,403.48 |
| 经营活动产生的现金流量净额 | -81,324,633.68 | -232,044,236.63 | 89,754,043.1 | 7,284,554.67 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 5,174,882,890.03 | 3,623,256,933.71 | 4,978,263,799.47 | 4,087,759,401.77 |
| 投资活动现金流出小计 | 4,913,860,883.86 | 3,307,708,931.6 | 5,737,272,531.46 | 4,164,756,502.09 |
| 投资活动产生的现金流量净额 | 261,022,006.17 | 315,548,002.11 | -759,008,731.99 | -76,997,100.32 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 136,036,105.79 | 67,369,965.82 | 343,558,490.81 | 251,925,755.55 |
| 筹资活动现金流出小计 | 186,357,797.64 | 60,110,989.4 | 343,086,830.2 | 240,742,040.19 |
| 筹资活动产生的现金流量净额 | -50,321,691.85 | 7,258,976.42 | 471,660.61 | 11,183,715.36 |
| 汇率变动对现金及现金等价物的影响 | -25,684,302.87 | -12,590,723.87 | -13,270,093.55 | -4,670,237.65 |
| 现金及现金等价物净增加额 | 103,691,377.77 | 78,172,018.03 | -682,053,121.83 | -63,199,067.94 |
| 期末现金及现金等价物余额 | 1,448,644,082.44 | 1,423,124,722.7 | 1,344,952,704.67 | 1,963,806,758.56 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 103,691,377.77 | - | -682,053,121.83 | - |